6/29/2011

Novo Nordisk filed for FDA approval to promote once-daily injectable drug Victoza with a long-acting insulin to treat type 2 diabetes. "The study that forms the basis for [this application] was a study with our own long-acting insulin, Levemir," said spokesman Mike Rulis.

Full Story:
Reuters

Related Summaries